Abrisqueta P, Karimi YH, Morillo D, Cordoba R, Phillips T, de Vos S, Nijland M, Offner F, Andersson P-O, Brody J, Cheah CY, Prieto PG, Hellström M, Jørgensen JM, Lewis D, Linton KM, Musuraca G, Wang L, Marek J, Osei-Bonsu K, Risum M, Falchi L. Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trial. haematol [Internet]. 2020Sep.10 [cited 2026Mar.5];. Available from: https://haematologica.org/article/view/haematol.2025.300086